Tagged with

Belgium Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt also delivers a clear message about the importance of continued public and private investments in basic research to foster new…

Romania Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market in several years. She reveals that the perception of diabetes in Romania is skewed, as more than 50 percent of…

Belgium Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key international positions in commercial, pricing, and market access within the company. As a newcomer to Belgium, Aracil highlights the particularities…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

Belgium Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on to speak about the unique cluster dynamic which comes with managing the three markets and also highlights her priorities to…

Romania Market overview with data on growth areas, key therapeutic areas, generics/originators split and more. Made with Visme Infographic Maker   Romania pharma market growth and dynamics between 2018 and 2019 by segment. Made with Visme Infographic Maker

India The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker   Abbreviated New Drug Applications (ANDAs), whereby a company seeks authorisation from the US FDA for a generic copy of a previously approved…

India A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market.   Now accounting for over 90 percent of all prescriptions dispensed in the USA, generic drugs play a vital role within US healthcare and have come a long way since their use…

Morocco A new IQVIA study sponsored by LEMM, the Moroccan association of multinationals looked at 3,437 references sold on the private market, which represents 75 percent of the total pharma market, and shows that eight out of ten drugs on the Moroccan market are produced locally. Made with Visme Infographic Maker…

Morocco Ensuring the country’s “sanitary sovereignty” has long been a key policy for Morocco and its government. In order to encourage the local production of drugs, Law 17-04 was promulgated in 2006 requiring pharma companies to operate a manufacturing, control and storage site in order to apply for marketing authorization.  …

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists.   [For cancer treatment the country has been] quite successful in moving…